305 related articles for article (PubMed ID: 33273537)
21. Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma.
Su X; Wan Y; Xie L; Lin X; Zhao H; Ju X; Fang A
Med Sci Monit; 2019 Sep; 25():6691-6701. PubMed ID: 31489957
[TBL] [Abstract][Full Text] [Related]
22.
Hou L; Li Y; Wang Y; Xu D; Cui H; Xu X; Cong Y; Yu C
Dis Markers; 2018; 2018():4108919. PubMed ID: 30420903
[TBL] [Abstract][Full Text] [Related]
23. Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods.
Chen JW; Dhahbi J
Sci Rep; 2021 Jun; 11(1):13323. PubMed ID: 34172784
[TBL] [Abstract][Full Text] [Related]
24. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
25. RNA-Seq profiling of circular RNA in human lung adenocarcinoma and squamous cell carcinoma.
Wang C; Tan S; Liu WR; Lei Q; Qiao W; Wu Y; Liu X; Cheng W; Wei YQ; Peng Y; Li W
Mol Cancer; 2019 Sep; 18(1):134. PubMed ID: 31484581
[TBL] [Abstract][Full Text] [Related]
26. Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response.
Lucchetta M; da Piedade I; Mounir M; Vabistsevits M; Terkelsen T; Papaleo E
BMC Cancer; 2019 Aug; 19(1):824. PubMed ID: 31429720
[TBL] [Abstract][Full Text] [Related]
27. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
[TBL] [Abstract][Full Text] [Related]
28. Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer.
Zardawi SJ; O'Toole SA; Sutherland RL; Musgrove EA
Histol Histopathol; 2009 Mar; 24(3):385-98. PubMed ID: 19130408
[TBL] [Abstract][Full Text] [Related]
29. Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer.
Thaiparambil J; Dong J; Grimm SL; Perera D; Ambati CSR; Putluri V; Robertson MJ; Patel TD; Mistretta B; Gunaratne PH; Kim MP; Yustein JT; Putluri N; Coarfa C; El-Zein R
Cancer Med; 2023 Jan; 12(1):584-596. PubMed ID: 35676822
[TBL] [Abstract][Full Text] [Related]
30. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
31. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
[TBL] [Abstract][Full Text] [Related]
32. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
[TBL] [Abstract][Full Text] [Related]
33. p53-inducible gene 3 promotes cell migration and invasion by activating the FAK/Src pathway in lung adenocarcinoma.
Gu MM; Gao D; Yao PA; Yu L; Yang XD; Xing CG; Zhou J; Shang ZF; Li M
Cancer Sci; 2018 Dec; 109(12):3783-3793. PubMed ID: 30281878
[TBL] [Abstract][Full Text] [Related]
34. Plakophilin-2 accelerates cell proliferation and migration through activating EGFR signaling in lung adenocarcinoma.
Hao XL; Tian Z; Han F; Chen JP; Gao LY; Liu JY
Pathol Res Pract; 2019 Jul; 215(7):152438. PubMed ID: 31126818
[TBL] [Abstract][Full Text] [Related]
35. ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer.
Napoli M; Wu SJ; Gore BL; Abbas HA; Lee K; Checker R; Dhar S; Rajapakshe K; Tan AC; Lee MG; Coarfa C; Flores ER
Nat Commun; 2022 Feb; 13(1):614. PubMed ID: 35105868
[TBL] [Abstract][Full Text] [Related]
36. High
Xie L; Dang Y; Guo J; Sun X; Xie T; Zhang L; Yan Z; Amin H; Guo X
Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634629
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma.
Qu Y; Cheng B; Shao N; Jia Y; Song Q; Tan B; Wang J
Aging (Albany NY); 2020 Mar; 12(6):4757-4777. PubMed ID: 32209727
[TBL] [Abstract][Full Text] [Related]
38. The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases.
Liang Y; Lei Y; Du M; Liang M; Liu Z; Li X; Gao Y
J Cell Mol Med; 2021 Jul; 25(14):7039-7051. PubMed ID: 34117717
[TBL] [Abstract][Full Text] [Related]
39. Shared network pattern of lung squamous carcinoma and adenocarcinoma illuminates therapeutic targets for non-small cell lung cancer.
Li P; Kuang X; Zhang T; Ma L
Front Surg; 2022; 9():958479. PubMed ID: 36263088
[TBL] [Abstract][Full Text] [Related]
40. Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma.
Tuna M; Mills GB; Amos CI
Neoplasia; 2023 Nov; 45():100932. PubMed ID: 37801862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
